Applications of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms in Parkinson's Disease
Received: 06-Feb-2018 / Accepted Date: 09-Feb-2018 / Published Date: 16-Feb-2018 DOI: 10.4172/2161-0460.1000424
Keywords: Parkinson’s disease; Repetitive transcranial magnetic stimulation; Primary motor cortex; Supplementary motor cortex; Neurorehabilitation
Repetitive Transcranial Magnetic Stimulation
Repetitive transcranial magnetic stimulation (rTMS) is a valuable non-invasive brain stimulation tool for interventional neurophysiology applications. It is used to modulate brain activity in specific, distributed, cortico-subcortical networks [1]. rTMS induces electric currents in the brain by producing a magnetic field perpendicular to the coil plane. This magnetic field is made to pass through the skull. The induced currents either activate neurons or induce synaptic plasticity by acting upon interneurons in the brain [2]. There are two main rTMS stimulation coil shapes namely the circular coil shape, which enables wide stimulation and the figure-of-8 coil shape, which permits focal stimulation. However, new coils that enable wide and deep stimulation are being developed [3,4], and it is becoming more common to select a coil based on the disease and site of stimulation. rTMS produces a sustained effect even after the end of the stimulation through repetitive application of stimuli with a specific rhythm. Stimulation parameters, mainly frequency, influence its modulatory effect in terms of resulting excitation or inhibition. High-frequency stimulation (often defined as being ≥ 5 Hz) has been shown to facilitate cortical excitability, whereas low-frequency stimulation (≤ 1 Hz) was shown to decrease or control cortical excitability. The most prevalent side-effects are discomfort and complaints of headache. These are mostly no serious adverse effects. Although seizures have been reported as a critical adverse effect, the current state of knowledge favors increasing stimulation frequency rather than intensity for reasons of safety defined according to the risk of seizures [5].
Parkinson's Disease
Parkinson’s disease (PD), the second most common neurodegenerative disease, is a progressive debilitating neurodegenerative disease that affects dopaminergic neurotransmission, thereby resulting in motor and non-motor symptoms. Motor dysfunction in PD is mainly manifested as resting tremors, rigidity, bradykinesia and postural instability [6]. Various therapeutic approaches have been developed for the treatment of PD. Pascual-Leone et al. first reported improvement in upper extremity movements in PD patients who had received rTMS. Many studies concerning the use of rTMS in PD have focused on its beneficial effects on motor function. A study involving meta-analyses found modest efficacy of high-frequency rTMS on motor function in PD [7,8]. rTMS also has the potential to be used for clinical therapy, as several available studies involving PD patients have shown.
Area for Stimulation
The systematic review [9] demonstrated the therapeutic effects of rTMS on motor symptoms in PD, as evaluated with the motor section of the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III). However, the best area of the brain for stimulation remains unknown, various cortical targets, including the primary motor cortex (M1), supplementary motor area (SMA), and left dorsolateral prefrontal cortex (DLPFC), has been reported. After application of high-frequency (HF)-rTMS over the M1, most studies have demonstrated that PD patient’s exhibit improved motor function in their hands and gait [10-12]. The HF-rTMS over the M1 suggested being increased motor-related activity in the caudate nucleus. Even so, other studies have reported no beneficial effects of this stimulation [13]. In one study, an rTMS of 5 Hz over the SMA modestly improved motor symptoms in patients with PD [14]. Another study, which aimed to improve disturbance in mood in PD patients by applying rTMS over the DLPFC, demonstrated positive effects on depression level [15]. Moreover, a few other studies have reported positive effects and improvement in motor symptoms in PD patients who received rTMS over the DLPFC [16]. Therefore, optimal parameters for rTMS remain to be established. To address this issue, we sought to identify the best cortical area for HF-rTMS therapy in patients with PD by conducting a double-blind, placebo-controlled, crossover study. After application of HF-rTMS over the M1, SMA, DLPFC and sham, we compared the results to those obtained during sham stimulations [17]. This study reported that the UPDRS-III scores following the application of HF-rTMS over the M1 and SMA was significantly greater than that following sham stimulation. In contrast, changes in UPDRS-III scores following bilateral rTMS over the DLPFC were not different from those after sham stimulation. No significant changes emerged for either the depression or apathy scores following HF-rTMS over any cortical area. Therefore, application of HF-rTMS over the M1 and SMA significantly improved the motor symptoms in patients with PD but did not improve mood disturbances. Many positive studies report improvement of bradykinesia, but diverge in their efficacy to treat other cardinal symptoms of PD. rTMS improved gait in several [18,19], but not all studies [20]. A few studies have reported finding improvement in tremor symptoms in PD patients who received rTMS. At present, the mechanisms of rTMS in relation to disturbances in motor function and mood in PD remain unclear and thus controversial. A hypoactive caudate nucleus may underlie the motor deficits in PD patients by interfering with the normal functioning of the striato-frontal motor loop. Applying HF-rTMS over the M1 may partially compensate for the underactive basal ganglia-thalamocortical outflow to the frontal motor cortical areas and induce lasting enhancement in cortical excitability, thus leading to clinical improvement. Strafella et al. [21] showed that applying rTMS over the M1 increased dopamine release in the nigrostriatal system. On the other hand, SMA is suggested be important in motor planning and preparatory processes in PD [22]. The studies using positron emission computerized tomography for cortical activation in PD patients with akinesia-predominant Parkinsonism suggested the involvement of hypoactive SMA and dorsal premotor areas [23]. Decreased activity in the SMA was considered to be due to less efferent feedback from the basal ganglia-thalamocortical motor loop A randomized clinical trial reported that HF-rTMS (5 Hz) over the SMA could modestly ameliorate motor symptoms in patients with PD [17]. However, in a subsequent study, the same authors reported long-lasting therapeutic benefits of LF-rTMS (1 Hz) over the SMA, but not of HF-rTMS (10 Hz) over the same area or the realistic sham stimulation [24]. Moreover, a recent subgroup analysis in a metaanalysis study demonstrated that HF-rTMS over the M1 and LF-rTMS over other frontal regions, including the SMA, could have a positive effect [25]. Yokoe et al. [17] demonstrated the positive effect of HFrTMS over the M1 and SMA on motor symptoms in patients with PD [17]. However, there are some limitations of a crossover design, which include carry-over effects and order effects. Unlike single session rTMS, multi-session cumulative rTMS might provide a long-lasting effect in cortical excitability and function [26,27]. The postsynaptic changes and expansion of plasticity might underlie the cumulative long-lasting effect of rTMS [19].
Summary
The rationale for non-invasive brain stimulation in clinical practice is to provide additional benefit beyond conventional therapy. Future studies need to explore stimulation parameters with regards to efficacy and safety. In addition, these studies need to identify neurophysiological correlates of clinical outcome measures which will allow for the determination of superior stimulation patterns and therapeutic strategies for the improvement of PD and other disorders.
Acknowledgement
This study was partly supported by Grant-in-Aid for Scientific Research (KAKENHI) (No.17K17843) and Magnetic Health Science Foundation.
References
- Fregni F, Freedman S, Pascual-Leone A (2007) Recent advances in the treatment of chronic pain with non-invasive brain stimulation techniques. Lancet Neurol 6: 188-191.
- Chervyakov AV, Chernyavsky AY, Sinitsyn DO, Piradov MA (2005) Possible mechanisms underlying the therapeutic effects of transcranial magnetic stimulation. Front Hum Neurosci 9: 303.
- Shimizu T, Hosomi K, Maruo T, Goto Y, Yokoe M, et al. (2017) Efficacy of deep rTMS for neuropathic pain in the lower limb: A randomized, double-blind crossover trial of an H-coil and figure-8 coil. J Neurosurg 127: 1172-1180.
- Cohen OS, Orlev Y, Yahalom G, Amiaz R, Nitsan Z, et al. (2016) Repetitive deep transcranial magnetic stimulation for motor symptoms in Parkinson’s disease: A feasibility study. Clin Neurol Neurosurg 140: 73-78.
- Rossini PM, Burke D, Chen R, Cohen LG, Daskalakis Z, et al. (2015) Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee. Clin Neurophysiol 126: 1071-1107.
- Jankovic J (2008) Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79: 368-376.
- Fregni F, Simon DK, Wu A, Pascual-Leone A (2005) Non-invasive brain stimulation for Parkinson's disease: A systematic review and meta-analysis of the literature. J Neurol Neurosurg Psychiatry 76: 1614-1623.
- Elahi B, Elahi B, Chen R (2009) Effect of transcranial magnetic stimulation on Parkinson motor function - Systematic review of controlled clinical trials. Mov Disord 24: 357-363.
- Chou YH, Hickey PT, Sundman M, Song AW, Chen NK (2015) Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: A systematic review and meta-analysis. JAMA Neurol 72: 432-440.
- Lefaucheur JP, Drouot X, Von Raison F, Ménard-Lefaucheur I, Cesaro P, et al. (2004) Improvement of motor performance and modulation of cortical excitability by repetitive transcranial magnetic stimulation of the motor cortex in Parkinson’s disease. Clin Neurophysiol 115: 2530-2541.
- Maruo T, Hosomi K, Shimokawa T, Kishima H, Oshino S, et al. (2013) High-frequency repetitive transcranial magnetic stimulation over the primary foot motor area in Parkinson’s disease. Brain Stimul 6: 884-891.
- Brys M, Fox MD, Agarwal S, Biagioni M, Dacpano G, et al. (2016) Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial. Neurology 87: 1907-1915.
- Ghabra MB, Hallett M, Wassermann EM (1999) Simultaneous repetitive transcranial magnetic stimulation does not speed fine movement in PD. Neurology 52: 768-770.
- Hamada M, Ugawa Y, Tsuji S; Effectiveness of rTMS on Parkinson's Disease Study Group, Japan (2008) High-frequency rTMS over the supplementary motor area for treatment of Parkinson's disease. Mov Disord 23: 1524-1531.
- Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N (2010) The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double-blind, placebo-controlled study. Mov Disord 25: 2311-2317.
- del Olmo MF, Bello O, Cudeiro J (2017) Transcranial magnetic stimulation over dorsolateral prefrontal cortex in Parkinson's disease. Clin Neurophysiol 118: 131-139.
- Yokoe M, Mano T, Maruo T, Hosomi K, Shimokawa T, et al. (2018) The optimal stimulation site for high-frequency repetitive transcranial magnetic stimulation in parkinson's disease: A double-blind crossover pilot study. J Clin Neurosci 47: 72-78.
- Khedr EM, Rothwell JC, Shawky OA, Ahmed MA, Hamdy A (2006) Effect of daily 10 repetitive transcranial magnetic stimulation on motor performance in Parkinson’s disease. Mov Disord 21: 2201-2205.
- Lomarev MP, Kanchana S, Bara-Jimenez W, Iyer M, Wassermann EM, et al. (2006) Placebo-controlled study of rTMS for the treatment of Parkinson's disease. Mov Disord 21: 325-331.
- Benninger DH, Iseki K, Kranick S, Luckenbaugh DA, Houdayer E, et al. (2012) Controlled study of 50-Hz repetitive transcranial magnetic stimulation for the treatment of Parkinson disease. Neurorehabil Neural Repair 26: 1096-1105.
- Strafella AP, Paus T, Fraraccio M, Dagher A (2003) Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain 126: 2609-2615.
- Cunnington R, Iansek R, Thickbroom GW, Laing BA, Mastaglia FL, et al. (1996) Effects of magnetic stimulation over supplementary motor area on movement in Parkinson’s disease. Brain 119: 815-822.
- Brooks DJ (1997) PET and SPECT studies in Parkinson’s disease. Baillieres Clin Neurol 6: 69-87.
- Shirota Y, Ohtsu H, Hamada M, Enomoto H, Ugawa Y (2013) Supplementary motor area stimulation for Parkinson disease: A randomized controlled study. Neurology 1180: 1400-1405.
- Elahi B, Chen R (2009) Effect of transcranial magnetic stimulation on Parkinson motor function--systematic review of controlled clinical trials. Mov Disord 24: 357-363.
- Bäumer T, Lange R, Liepert J, Weiller C, Siebner HR, et al. (2003) Repeated premotor rTMS leads to cumulative plastic changes of motor cortex excitability in humans. Neuroimage 20: 550-560.
- Chang WH, Kim YH, Bang OY, Kim ST, Park YH, et al. (2010) Long-term effects of rTMS on motor recovery in patients after sub acute stroke. J Rehabil Med 42: 758-764.
Citation: Mano T, Yokoe M, Saitoh Y (2018) Applications of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms in Parkinson’s Disease. J Alzheimers Dis Parkinsonism 8: 424. DOI:
Copyright: ©2018 Mano T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
ºÚÁÏÍø Journals
Article Tools
Article Usage
- Total views: 4981
- [From(publication date): 0-2018 - Nov 25, 2024]
- Breakdown by view type
- HTML page views: 4265
- PDF downloads: 716
